Last updated on March 2020

A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Brief description of study

This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of tumor necrosis factor alpha-inadequate responders (TNF-IR) subjects with active Psoriatic Arthritis (PsA).

Clinical Study Identifier: NCT03896581

Find a site near you

Start Over

Pa0011 30005

Camberwell, Australia
  Connect »

Pa0011 30001

Footscray, Australia
  Connect »